Trials / Completed
CompletedNCT00002014
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and tolerance of various combinations of zidovudine (AZT) and didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent AZT and ddI administered orally. To evaluate the antiviral, immunologic and virologic effects of AZT and ddI administered concurrently.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zidovudine | |
| DRUG | Didanosine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002014. Inclusion in this directory is not an endorsement.